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Steady-state levels of HIV-1 viraemia in the plasma vary more than a 1000-fold between HIV-positive
patients and are thought to be in£uenced by several di¡erent host and viral factors such as host target cell
availability, host anti-HIV immune response and the virulence of the virus. Previous mathematical
models have taken the form of classical ecological food-chain models and are unable to account for this
multifactorial nature of the disease. These models suggest that the steady-state viral load (i.e. the set-
point) is determined by immune response parameters only. We have devised a generalized consensus
model in which the conventional parameters are replaced by so-called p`rocess functions’. This very
general approach yields results that are insensitive to the precise form of the mathematical model. Here
we applied the approach to HIV-1 infections by estimating the steady-state values of several process
functions from published patient data. Importantly, these estimates are generic because they are
independent of the precise form of the underlying processes. We recorded the variation in the estimated
steady- state values of the process functions in a group of HIV-1 patients. We developed a novel model by
providing explicit expressions for the process functions having the highest patient-to-patient variation in
their estimated values. Small variations from patient to patient for several parameters of the new model
collectively accounted for the large variations observed in the steady-state viral burden. The novel model
remains in full agreement with previous models and data.
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1. INTRODUCTION
HIV-1 infection is characterized by high levels of virus in
both the plasma and lymph nodes of infected individuals
during all stages of the disease (Embretson et al. 1993;
Pantaleo et al. 1993; Piatak et al. 1993). After an initial
peak of viraemia in primary infection, virus levels stabi-
lize around a certain set-point and typically increase only
slowly thereafter (Weiss 1993; Mellors et al. 1996). The
viral load is a steady-state balance between ongoing
extensive virus replication and rapid clearance (Ho et al.
1995; Wei et al. 1995; Perelson et al. 1996). The level of this
steady state, as re£ected by the virus titre in peripheral
blood, shows enormous variation from patient to patient.
Even after discarding the highest measurements, the
variation remains over 1000-fold (Piatak et al. 1993).
Moreover, the set-point is strongly correlated with the
rate of progression (Mellors et al. 1996). The steady- state
viral burden is in£uenced by several di¡erent host and
viral factors including target cell availability (De Boer &
Perelson 1998; De Boer et al. 1998; Orendi et al. 1998), the
humoral immune response (Fauci 1993), the cellular
immune response (Borrow et al. 1994; Rinaldo et al. 1995;
Borrow et al. 1997; Goulder et al. 1997; Ogg et al. 1998; Jin
et al. 1999; Schmitz et al. 1999) and virulence factors
(Deacon et al. 1995; Katzenstein et al. 1996).
Mathematical models of HIV-1 infection typically have
the form of an ecological food-chain model, with target
cells as the prey, productively infected cells as their
predator and the immune response as the top predator
(Nowak & Bangham 1996; De Boer & Perelson 1998). A
major problem with such models in both ecology (Arditi
& Ginzburg 1989; Ginzburg & Akc° akaya 1992; Abrams
1994; Kaunzinger & Morin 1998) and virology (De Boer
& Perelson 1998) is the strong dependence of steady-state
results on the precise form and length of the food chain.
For instance, in a typical cytotoxic T-cell model, large
variations in the HIV-1 burden require a similar variation
in a parameter called the `immune responsiveness’
(Nowak & Bangham 1996). However, such a variation,
which spans several orders of magnitude, is not easily
accounted for by a single biological attribute. Rather, it is
expected that several factors contribute to the variation.
Indeed, the experimental evidence cited above suggests
that several factors besides immune responsiveness play a
role.
Complications like this are typical of mathematical
food-chain models. A famous example from ecology is the
p`aradox of enrichment’ (Rosenzweig 1971), where
increasing the food availability of a prey population fails
to increase the steady-state level of that population.
Rather, it is the next level of the food chain, i.e. the
predator, that pro¢ts from the enrichment by an increase
in its steady-state level. Conversely, in a three-dimensional
food chain consisting of a prey, a predator and a top
predator population, only the prey and the top predator
ultimately bene¢t from an enrichment of the food avail-
ability of the prey. Generally, the correlations between the
steady states of the di¡erent populations in food-chain
models are determined by (i) the number of populations
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in the food chain, (ii) saturation e¡ects within the
di¡erent populations, and (iii) competition e¡ects within
the di¡erent populations (Arditi & Ginzburg 1989;
Ginzburg & Akc° akaya 1992; Abrams 1994; Kaunzinger &
Morin 1998). Whether or not mathematical models are in
agreement with, for example, the observed negative
correlation between the speci¢c CD8+ T-cell immune
response and the viral load (Ogg et al. 1998) or with the
positive correlation between the viral load and target cell
levels (Orendi et al. 1998) does not rest on a generic
property of the models. Instead, it depends on the length
of the food chain of the model and/or on the precise form
of the interaction terms.
Developing mathematical models for HIV-1 infection
that are simple enough to allow a good understanding
and realistic enough to allow small variations in several
factors to account collectively for large variations in the
viral burden during the asymptomatic quasi-steady state
remains a major challenge. The main objective of this
paper is to pick up this challenge by developing a novel
heuristic approach that allows the identi¢cation of the
processes controlling the steady-state levels. The approach
is applied here to a discussion of the factors controlling
HIV-1 during clinical latency.
2. A CONSENSUS MODEL WITH `PROCESS
FUNCTIONS’
We adopt a widely used minimal model of an HIV-1
infection (Nowak & Bangham 1996; Bonhoe¡er et al.
1997a,b; De Boer & Perelson 1998) written in the A`rden
notation’ (http ://www-binf.bio.uu.nl /¹rdb/arden.html).
The model considers target cells T , productively infected
cells I, virus V and immune e¡ector CD8+ Tcells E. The
structure of the model resembles an ecological food chain
of a prey T, its predator I with a life stage V and a top
predator E (De Boer & Perelson 1998). Since the steady-
state levels during HIV-1 clinical latency are changing on
a very slow time-scale of years, one typically studies the
equilibria of the model. The novelty of our approach
resides in the interpretation of the parameters of the
model: any p`arameter’ in equations (1)^ (4) is explicitly
allowed to be any function of the other p`arameters’ and/
or variables of the model. Because each p`arameter’ in
fact re£ects a process, we call each of them a p`rocess
function’. For example, the process ¼ by which target cells
are produced could be written as ¼ ˆ aQ , where aQ
represents the activation a of quiescent cells Q (Stilianakis
et al. 1997); the process ¬ of the activation of the immune
response could be written as a saturation function ¬
ˆ a/(h ‡ I) (De Boer & Perelson 1998) and the death
process ¯ of infected cells could be made dependent on
the immune response ¯ ˆ kE, where k is the killing rate.
This interpretation of parameters as processes allows us
to postpone the speci¢cation of the interaction between
the immune response E and equations (1)^(4). Thus, we
¢rst obtain generic results that are truly independent of
the form of this interaction.
We write our generalized consensus model as follows:
dT
dt
ˆ ¼¡ ¯TT ¡ ­ TV , (1)
dI
dt
ˆ f ­ TV ¡ ¯I , (2)
dV
dt
ˆ pI ¡ cV , (3)
dE
dt
ˆ ¬EI ¡ ¯EE, (4)
where the process function ¼ is the source of target cells,
­ is an infection process, f is the fraction of successful
infections, p represents the rate of virion production, c is
the virion clearance rate and ¬ is the immune responsive-
ness. All process functions ¯ determine death rates. One
can easily see that this comprises a three-dimensional
food chain because the fast time-scale of equation (3)
typically allows for its replacement by the quasi-steady-
state assumption V ˆ ( p/c)I .
One obtains the steady-state expressions
I^ ˆ ¯E
¬
, (5)
V^ ˆ p
c
I^ , (6)
and
T^ ˆ ¼
¯T ‡ ­ V^
ˆ c¬¼
c¬¯T ‡ p­ ¯E
(7)
from equations (4), (3) and (1), respectively. Equation (5)
suggests that the only factors determining the steady- state
level of productively infected cells I^ are the `immune
responsiveness’ ¬ and the death rate of immune e¡ectors
¯E (Nowak & Bangham 1996). Because one expects ¯E to
vary little between patients, large variations in I^ would
require similar variations in ¬. Other factors such as
target cell availability and viral virulence seem to have no
e¡ect whatsoever in controlling I^ because they are not
re£ected in either ¯E or ¬. This is a generalization of an
earlier study (Nowak & Bangham 1996) because we have
not speci¢ed the e¡ect of the immune response on the
system beforehand.
Formally, it is not known whether patients di¡ering by
orders of magnitude in their viral load in the peripheral
blood (Mellors et al. 1996) also have large di¡erences in
the total body counts of productively infected cells I^.
From equation (6), di¡erences in the viral production p
and in the viral clearance c could contribute to the
observed variations in V^. However, there is little indica-
tion that patients di¡er markedly in p (Haase et al. 1996;
Hockett et al. 1999) or in c (Perelson et al. 1996; Mittler
et al. 1999; Ramratnam et al. 1999). Moreover, there is
good correlation between the numbers of productively
infected cells and the amounts of virus in the lymphoid
tissue or in the peripheral blood (Hockett et al. 1999).
Finally, the fact that the viral burden in the peripheral
blood is a good predictor of the rate of disease progression
(Mellors et al. 1996) also suggests that patients with a
high viral load do have a severe infection, i.e. do have a
high I^. In this paper we therefore wish to explain large
di¡erences in I^ with small di¡erences in parameter
values. Equation (5) fails to account for this: large di¡er-
ences in I^ require large di¡erences in ¬.
Because there is no explicit connection between
equation (4) and the rest of the system, we cannot
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determine the steady state E^. However, for the special
case where E^ ˆ 0 or where E^ is at a constant (e.g.
maximum) level, one can drop equation (4) from the
system and obtain a target-cell-limited solution (McLean
et al. 1991; McLean & Nowak 1992; De Boer & Perelson
1998) from equations (2), (1) and (3), respectively, i.e.
T^ ˆ ¯c
f ­ p
, (8)
I^ ˆ ¼f
¯
¡ ¯T c
­ p
, (9)
and
V^ ˆ p
c
I^ : (10)
These steady-state expressions di¡er radically from the
expressions in equations (5)^(7). This illustrates the
problem outlined in ½ 1, i.e. that steady states in a food-
chain model depend crucially on its form and length
(Arditi & Ginzburg 1989; Ginzburg & Akc° akaya 1992;
Abrams 1994; Kaunzinger & Morin 1998).
3. PUBLISHED ESTIMATED VALUES
Several steady-state values of the process functions and
the variables of this consensus model have been estimated
previously. For the turnover of productively infected cells
we use the consensus estimate of ¯ ’ 0:5/d (Ho et al. 1995;
Wei et al. 1995; Klenerman et al. 1996; Perelson et al. 1996;
Notermans et al. 1998). Between patients there is
remarkably little variation in ¯. Recent plasmapheresis
experiments have provided novel estimates of 40^110 min
for the half-life of HIV virions (Mittler et al. 1999;
Ramratnam et al. 1999). An intermediate value is there-
fore 75min, i.e. c ˆ 13/d, but little is known about the
patient-to-patient variation in c. Estimates for the
production rate p vary between a few hundred (Haase
et al. 1996) and a few thousand (Hockett et al. 1999). The
latter study suggested that there is little variation in p
between patients di¡ering markedly in their viral burden
(Hockett et al. 1999). The death rate of HIV-1-speci¢c
CD8+ e¡ector cells during anti-retroviral therapy has
been estimated by a tetramer assay as ¯E ˆ 0:015/d (Ogg
et al. 1999). Most of the virus is trapped on the surface of
follicular dendritic cells (FDCs) (Pantaleo et al. 1993;
Hockett et al. 1999), with an average pool size of order of
magnitude 1010 particles in the lymphoid tissue (Cavert
et al. 1997). In di¡erent studies addressing the lymphoid
tissue, the total body counts of productively infected cells
have varied between 107 (Chun et al. 1997) and 108
(Cavert et al. 1997).
We will assume here that dividing CD4+ T cells form
the main pool of target cells. Since, for human CD4+
Tcells, cell division takes approximately a day (Fleury
et al. 1998), we assume that ¯T ’ 1/d. Identifying dividing
CD4+ T cells in the lymphoid tissue with the Ki67
monoclonal antibody yields estimates varying around 109
target cells (Fleury et al. 1998; Zhang et al. 1998). In addi-
tion, labelling studies with 2H-glucose have suggested
that the percentage of dividing CD4+ T cells is 1% in
healthy controls and 3^5% in HIV-1 patients (Hellerstein
et al. 1999). Having approximately 2:5 £ 1011 CD4+
Tcells this also suggests a total body count of approxi-
mately 109 target cells.
(a) Estimating values of process functions
The approach developed here is an attempt to breach
the non-robustness of results obtained by solving for
steady-state levels in food-chain models. In order to
obtain generic results a `consensus’ model that is a gener-
alization of many di¡erent more detailed models having
di¡erent explicit expressions for the di¡erent process
functions is required. The model in equations (1)^ (4) is a
good example of such a consensus model. Here we solve
the inverse problem of estimating the values of process
functions by substitution of observable parameters and
steady states into equations (1)^ (4). Because the values of
the process functions are solved directly from the steady
state of the di¡erential equations, these values remain
valid for all possible functional realizations of the
consensus model. Thus, any such estimate provides a
generic numerical value of the corresponding process for
the particular steady state at hand. Process functions with
little variation in their estimated values can be explicitly
written as constants, i.e. as parameters. On the other
hand, ¢nding a large patient-to-p atient variation in the
estimated values of a process function suggests an explicit
expression involving variables and novel parameters.
Thus, we estimate the values of process functions in
terms of observable steady-state levels T^ , I^ and V^ and
measured parameter values ¯ and ¯E. Rewriting equation
(3) yields an estimate for the production scaled by the
clearance time, i.e.
p/c ˆ V^ /I^ , (11)
and rewriting equation (4) gives
¬ ˆ ¯E/I^. (12)
The steady state of equation (2) gives
­ ˆ ¯
f
I^
V^T^
ˆ ¯c
fpT^
, (13)
and, hence, from equation (1) we obtain that
¼ ˆ ¯T T^ ‡
¯
f
I^ . (14)
Note again that these expressions are obtained for any
form of immune control in the consensus model, i.e. they
are obtained without specifying the interaction between
the immune e¡ectors E and the remainder of the system.
In order to illustrate basic principles, we estimate the
values of process functions from previously published data
on approximately ten HIV-1-infected asymptomatic
patients. The data in table 1 compile estimates from three
di¡erent papers providing (i) I^ and V^, i.e. the number of
productively infected cells and virions trapped on FDCs
in lymphoid tissue (Cavert et al. 1997), (ii) T^, i.e. the
number of dividing CD4+ T cells in lymphoid tissue
(Zhang et al. 1998), and (iii) ,¯ i.e. the death rates of
productively infected cells (Notermans et al. 1998).
Knowing I^ and V^ we can estimate p/c from equation (11).
Since there is no information on the value of f , we calcu-
late f ­ from equation (13). Not knowing f we are not yet
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able to use equation (14) in estimating ¼. As noted above,
the estimates listed in table 1 re£ect true `values’ of the
corresponding process in that patient. The variation in
these estimates therefore provides generic information
about the variation in the processes determining the viral
load in each patient. As a measure of the variation in
each column, the bottom row of table 1 shows the ratio of
the highest over the lowest value of each variable or
process. The ¢rst line of table 1 gives a t`ypical patient’,
corresponding to a rounded average of the data.
The variation in this data set seems considerably less
than the typical orders of magnitude variation (Mellors
et al. 1996). The variations in V^ and I^ are `only’ 17-fold
and 24-fold, respectively (see table 1). This is partly due to
the fact that we considered the lymphoid tissue. In
peripheral blood the variation in the viral load is
approximately 100-fold (Notermans et al. 1998). However,
in this patient set, the viral load in the peripheral blood is
not correlated with either V^ or I^ in the lymphoid tissue.
Because the total body viral load is largely con¢ned to
the lymphoid tissue, here we only consider lymphoid
tissue data. We will return to the issue of explaining the
orders of magnitude variation in ¢gure 1.
Although we found a reasonable correlation between I^
and V^ (r ˆ 0:79 and p50:01) in this study, the 8.5-fold
variation in p/c demonstrates that there is still consider-
able variation in the V^ /I^ ratio. Note that there is a
discrepancy with the study of Hockett et al. (1999) who
found V^ /I^ ratios that were an order of magnitude larger.
This is probably due to di¡erent measurement techniques.
In the data sets used for the present paper and with the
intermediate estimate of c ˆ 13/d (Mittler et al. 1999;
Ramratnam et al. 1999) we obtained production rates p of
a few thousand virions per cell per day. The observed
8.5-fold variation could obviously be due to patient di¡er-
ences in c, p or in the retention of virus particles in the
lymphoid tissue. Finally, the two process functions that
vary most are ¬ and f ­ .
4. EXPLICIT EXPRESSIONS FOR PROCESS
FUNCTIONS
(a) The cytotoxic model
One can retrieve previous cytotoxic control models by
allowing the process ¯ to depend on the immune
response. For example, one could write
¯ ˆ ¯I ‡ ¬kE, (15)
or
¯ ˆ ¯I ‡ kE, (16)
where ¯I is the normal death rate and kE represents the
cytotoxic killing of productively infected cells. In the
model of Nowak & Bangham (1996) the killing is
weighted by the immune responsiveness ¬, as in
equation (15). Using equations (11)^ (14) and setting f ˆ 1,
one can again calculate ¬, p/c, ­ and ¼ for every patient
in table 1 in order to obtain the correct steady state with
either of these models. The novel parameters ¯I and k
only change the steady-state immune response E^ and no
other variable of the system. They can be changed freely
provided that ¯I5¯ and E^40.
Having speci¢ed the e¡ect of the immune response in
equations (15) and (16) one may solve for the steady-
state level E^. However, the form of the steady- state
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Table 1. Clinical data and the corresponding numerical estimates
(The number of productively infected cells I^ was calculated from table 1 in Cavert et al. (1997) by multiplying the column
`number of mononuclear cells (MNC) per gram of lymphoid tissue (LT) with 420 copies of HIV per cell’ by the expected 700 g
of lymphoid tissue in a 70 kg individual. Similarly, the steady-state viral burden V^ in lymphoid tissue was calculated by
multiplying the column `number of copies of HIV RNA per gram of LT on follicular dendritic cells (FDC)’ in the same table by
0:5 £ 700 because viral RNA is double stranded and because of the 700 g of lymphoid tissue. Because the vast majority of the
virions are associated with FDCs in lymphoid tissue (Cavert et al. 1997), this should provide a fair estimate of the total body
burden. The number of target cells T^ was calculated from table 2 in Zhang et al. (1998) by multiplying the CD4+ T cell count
per microgram of lymphoid tissue by 700 £ 106 and by the fraction of Ki67+ CD4+ in lymphoid tissue. The death rates ¯ of
productively infected cells were copied from table 1 in Notermans et al. (1998). The values are estimated by the expressions in
equations (11) (^14) derived in the text. Constant parameter values: ¯T ˆ 1, ¯I ˆ 0:1, ¯E ˆ 0:015, E0 ˆ 8, k ˆ 10, a ˆ 1 and
h ˆ 106. The identi¢cation number of each patient in column 1 is a compilation of those used in Cavert et al. (1997), Notermans
et al. (1998) and Zhang et al. (1998), respectively.)
ID
number
I^
(cells)
V^
(virions)
T^
(cells)
¯
(day¡1)
¬
(cell¡1
day ¡1)
p /c
virions
cell¡1)
f ­
(virions¡1
day¡1)
e
(%¡1)
­
(virions¡1
day¡1)
¼
(cells
day¡1)
E^
(%) f
typ ical 108 1010 109 0.50 1.5£10¡10 100 5£10¡12 40.6 8.5£10¡11 1.9£109 1.60 0.059
48 910 3.2£ 108 1011 ö 0.37 4.7£ 10¡11 326 ö 54.8 ö ö 1.19 0.077
49 021 6.8£ 108 5.6£ 1010 1.1£ 109 0.89 2.2£ 10¡11 82 10¡11 70.2 1.1£ 10¡10 7.3£ 109 0.93 0.097
44 935 1.8£ 108 1.2£ 1011 1.4£ 109 0.34 8.6£ 10¡11 700 3.4£ 10¡13 46.4 5.1£ 10¡12 2.3£ 109 1.41 0.066
45 242 2.8£ 107 7£ 109 1.3£ 109 0.51 5.4£ 10¡10 250 1.5£ 10¡12 31.0 3.3£ 10¡11 1.6£ 109 2.04 0.047
49 156 3.5£ 108 7£ 1010 1.4£ 109 0.46 4.3£ 10¡11 200 1.6£ 10¡12 56.2 2£ 10¡11 3.5£ 109 1.16 0.079
49 777 9.8£ 107 4.6£ 1010 3.1£ 108 0.60 1.5£ 10¡10 464 4.1£ 10¡12 40.4 7£ 10¡11 1.3£ 109 1.61 0.059
49 684 1.4£ 108 2.2£ 1010 5.1£ 108 0.37 1.1£ 10¡10 155 4.6£ 10¡12 43.9 7.3£ 10¡11 1.3£ 109 1.48 0.063
44 699 4.6£ 107 8.8£ 109 ö 0.52 3.3£ 10¡10 192 ö 34.3 ö ö 1.87 0.051
48 503 108 4.6£ 1010 1.5£ 109 0.36 1.4£ 10¡10 433 5.6£ 10¡13 41.1 9.4£ 10¡12 2.1£ 109 1.58 0.059
ratio 24 17 4.8 2.4 24 8.5 29 2.3 22 5.6 2.2 2.1
expression strongly depends on the form of the model.
With equation (15) it is a non-monotonic function of the
immune responsiveness ¬ (Nowak & Bangham 1996)
and with equation (16) it is an increasing saturation func-
tion of ¬. Moreover, one may study models that are totally
independent of target cell levels by letting f ˆ 1/T . In
such models E^ is either independent of ¬ (with equation
(16)) or an inverse function of ¬ (with equation (15)).Thus,
these four cytotoxic models all have di¡erent predictions
for the relation between the steady-state immune response
E^ and ¬ and, hence (see equations (5) and (6)), for the
relation between E^ and the viral load V^. Having such non-
generic predictions it seems impossible to conclude
whether or not cytotoxic control models are in agreement
with the observed strong negative correlation between the
viral burden V^ and the cytotoxic immune response E^ as
reported by Ogg et al. (1998). Finally, in all of these
models, the large variation in the viral burden can only be
attributed to large variations in the immune responsiveness
¬ (and, more unlikely, in the turnover of the immune
response ¯E) (see equation (5) and Nowak & Bangham
(1996)). We have argued above that such large variations
in ¬ are likely to involve a number of hidden factors.
(b) Employing the variation in the estimated values
An important point of this paper is using the di¡er-
ences in the patient-to-patient variation in the various
process functions in order to incorporate more biology
into the model. First, both ¬ and f ­ are process functions
that vary widely. If the number of productively infected
cells I generally varies by orders of magnitude between
patients (Mellors et al. 1996), ¬ would also have to vary
by orders of magnitude (Nowak & Bangham 1996). To us
this suggests that ¬ is not a `true’ parameter and is,
indeed, more likely to re£ect a process. Second, there is
generally little variation between HIV-1-positive patients
in the turnover ¯ of productively infected cells (Ho et al.
1995; Wei et al. 1995; Klenerman et al. 1996; Perelson et al.
1996). By our process function approach this would
suggest that ¯ can be explicitly expressed as a constant
and that the cytotoxic expressions written above need not
be the most appropriate choice for the e¡ect of the
immune response. An alternative possibility is that most
of the infected cells are removed by cytotoxic T lympho-
cytes (CTLs) before they start to produce virus in large
quantities (Klenerman et al. 1996). Since this can be
incorporated by writing the process function f as an
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Figure 1. Analysis of the e¡ects of small parameter variations in the `early cytotoxic’ model of equations (1) (^4), (17) and (18).
The stable non-trivial equilibrium value I was calculated for 250 di¡erent parameter combinations of e, ­ and ¼ and plotted
against (a^c) the parameter values used, (d) the corresponding equilibrium value E, (e) the cytotoxicity level f , and ( f ) the
potential `target-cell-limited’ level IT in the case of an anti-CD8 treatment. The values of e, ­ and ¼ were independently drawn
from log-normal distributions, with a standard deviation such that 95% of the parameter values cover a threefold range around
the estimated parameter values of the `typical patient’ (see table 1). All other parameters are as described in the legend to
table 1. The parameter estimates and equilibrium values of the typical patient are indicated by the horizontal and vertical
lines. (d ) The dashed line indicates the Ogg et al. (1999) relationship. It is this ¢gure that sets our estimate of E0: by setting
E0 ˆ 8 in E^ ˆ E0 ¡ 0:8 log I, we allow the rightmost patients (having I^ ˆ 109) to still have an immune response of E^ ˆ 0:8%. At
I^ ˆ 1010 the immune response vanishes.
explicit expression involving the immune response E, this
would allow another process to account for part of the
variation in f ­ . Because of the data supporting a role of
target cell availability and viral virulence in setting the
steady-state viral burden, I^ should not only depend on
the immune responsiveness ¬, but should also depend on
the target cell production ¼ and the infection rate ­ . In
the consensus model this is not the case because the form
of equation (4) only allows for solving the steady state I^
from the immune response equation. Replacing ¬ by an
expression allowing the proliferation of E to be a compe-
titive saturation function of I (De Boer & Perelson 1998)
allows one to tune parameters such that the steady state
of equation (4) largely determines I^ (i.e. for e ! 0) or E^
(i.e. for h ! 0).
These biological constraints can be implemented in the
consensus model by writing the following expressions for
our process functions:
¬ ˆ a
h ‡ I
1
1 ‡ eE , (17)
and
f ˆ 1
1 ‡ kE , (18)
which allows for saturation in I and competition between
the E cells, and the cytotoxic response eliminates a
fraction of the recently infected cells. Note that ¯ now
remains independent of E. Equations (17) and (18) repre-
sent an `early cytotoxicity’ functional realization of the
consensus model of equations (1)^(4). The cytotoxic killing
of infected cells predominantly takes place in the earlier
stages of cellular infection before the infected cells start to
produce virus in large quantities (Klenerman et al. 1996).
Setting proper values of the parameters of this model
will yield the observed steady state. Thus, we can allow
for more biology by imposing additional biological
constraints on the values of e, ­ and ¼. The paper by Ogg
et al. (1998) established a well-de¢ned inverse relation
between the steady-state viral load and the CD8+ T-cell
response in the peripheral blood. From ¢g. 2B in Ogg
et al. (1998) we read that log‰RNAplasmaŠ ’ log‰RNA0Š
¡2 E^, where E^ is the CTL response measured as the
percentage of CTLs speci¢c for HIV-1 epitopes. The paper
by Hockett et al. (1999) allows us to compute the plasma
RNA viral load from the number of productively infected
cells in the tissue (i.e. I in the model) by their relation-
ship log‰RNAplasmaŠ ’ log‰RNA0Š ‡ 1:6 log‰I^Š. In combi-
nation, this yields the result that the expected immune
response is E^ ’ E0 ¡ 0:8 log‰I^Š. For our typical patient
this gives E ’ 1:6% as a typical value (see table 1). In
addition, experiments with SIV-infected macaques where
anti-CD8 treatment resulted in an enormous increase in
the viral burden (Jin et al. 1999; Schmitz et al. 1999) have
suggested that the CD8 immune response has a large
impact on the steady- state viral burden. Setting k ˆ 10
we achieve a removal of more than 95% of the infected
cells (see the f -values in table 1). Thus, a rapid increase in
the viral load is expected if one were to decrease E in
order to simulate an anti-CD8 treatment (see below).
Having estimated E^ from I^, we calculate the expected
value of f from equation (18). Knowing the expected f^ ,
we are able to compute ­ and ¼ from equations (13) and
(14). Because we know that CD8+ e¡ector T cells can
proliferate relatively fast, i.e. a ’ 1 day¡1 and because we
think that, due to the high antigen load, the immune
response to HIV should typically be saturated, i.e.
h ˆ 106 ½ I^ , we solve the competition parameter e from
equations (12) and (17) as
e ˆ 1
E^
aI^
¯E…h ‡ I^†
¡ 1 . (19)
This procedure yields a complete estimation of all process
functions for each individual patient in table 1. From the
constraints imposed on the values of e, ­ and ¼, we
naturally obtain steady states where the level of the
immune response follows the `Ogg et al. (1998)’ relation-
ship with the viral burden. In addition, the immune
response very e¡ectively clears recently infected cells in
all patients, i.e. in all patients f ½ 1. The 24-fold varia-
tion in ¬ is indeed resolved by small variations in e and ¼
(see table 1). Equation (19) yields high values for e, i.e.
strong competition. CD8 immune responses could indeed
be impaired during HIV infection due to a lack of HIV-
speci¢c helper T cells (Mori et al. 2000; Oxenius et al.
2000). Because eE^ ¾ 1 and h½ I^, the ¬EI proliferation
term in equation (4) is approaching the s`ource’ term
¼E ˆ a/e. Apparently, we need only small variations in
this source term.
The large variation in f ­ has been resolved by small
variations in f , but the variation in ­ has remained large.
The reason for this is that, if patients have a high V^ /I^
ratio, then one obtains a high estimate for their scaled
production rate p/c from equation (11). Hence, to account
for their relatively low I^, a low estimate for ­ is obtained
from equation (13). The large residual variation in ­
might be partly explained by di¡erent rates of retention
in the lymphoid tissue, provided that free and bound
virus particles have di¡erent infectivity.
The steady state turned out to be stable for all para-
meter values used in table 1 (and in ¢gure 1). Although
we have concentrated on a steady-state analysis, we did
check how our t`ypical patient’ would respond to an
anti-CD8 treatment ( Jin et al. 1999; Schmitz et al. 1999)
simulated by a large reduction of the e¡ector population
(e.g. E ˆ E^/100). Decreasing E this much sharply
increases f such that the viral load increases more than
tenfold in a few days. The target cells decrease on a
similarly rapid time-scale and a target-cell-limited steady
state is monotonically approached. However, thanks to
the high proliferation rate of a ˆ 1 day¡1, the e¡ector
population recovers on a time-scale of weeks. As a
consequence, the viral load decreases and target cells
recover and the pre-treatment equilibrium in table 1 is
approached monotonically on a time-scale of weeks (not
shown). This is in good agreement with other data (Jin
et al. 1999; Schmitz et al. 1999).
In order to demonstrate that small parameter varia-
tions in this model can also account for the typically
1000-fold variations in the viral burden, we vary the
values of e, ­ and ¼ around their typical value in ¢gure 1.
Taking the typical value for each parameter from table 1
as the mean of a log-normal distribution we set the
standard deviation such that 95% of the parameter
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values cover at most a threefold range around the mean.
Having drawn e, ­ and ¼ independently, we compute the
corresponding steady state of the system. We have plotted
each actual parameter value with its corresponding
steady state I^ in ¢gure 1a^ c. Allowing for this threefold
variation in e, ­ and ¼ only, we obtain a variation of
three orders of magnitude in I^. The immune response E^
and cytotoxicity level f as they are realized by these para-
meter values are plotted in ¢gure 1d,e. Figure 1f depicts
the expected e¡ect of the anti-CD8 treatment of Jin et al.
(1999) and Schmitz et al. (1999). The steady-state viral
burden expected in the absence of an immune response,
i.e. I^ as de¢ned by equation (9), is plotted on the y-axis.
Note that, over the entire range, this `target-cell-limited’
IT level remains much higher than the `immune-
controlled’ I^.
Our results demonstrate that, by the process function
approach, we have indeed achieved what we aimed for.
Variations in the viral burden are now collectively
accounted for by variations in (i) the target cell produc-
tion ¼, (ii) the CD8 competition e, and (iii) the infection
rate ­ . Moreover, in order to account for the three orders
of magnitude increase in the viral burden we only need a
threefold variation in ¼, ­ and e. This seems a natural
result because, by our present approach, processes
varying widely are replaced by explicit expressions in
terms of the dependent variables of the model and of new
parameters. It thus becomes possible to account for the
wide variation by combining smaller variations in several
parameters and/or variables of the new model.
5. CONCLUSIONS
Obviously, our estimated values of the process functions
remain crude approximations. For instance, it is probably
not correct to assume that all Ki67+ CD4+ T cells are
proper target cells for HIV-1. However, the estimates
presented here mainly serve as an illustration of the
process function approach that can be employed as a
heuristic way of allowing experimental data to guide
further model development. The parameter that retains
most variation is the infection rate ­ . Indeed, ­ could be
written as a function of the viral load V in order to re£ect
the di¡erential trapping on the FDC network (Hockett
et al. 1999).
Empirical studies into the factors controlling an HIV-1
infection during clinical latency have largely relied on
correlating the steady-state viraemia with steady levels of
the immune response (Ogg et al. 1998) and/or with target
cell availability (Orendi et al. 1998). However, such an
approach is not robust because di¡erent models predict
radically di¡erent correlations. The inverse problem of
estimating the values of processes from observed steady-
state values gives far more robust results. In addition, the
observed variations in these estimates suggested writing
explicit expressions for the underlying process. This
enabled us to develop novel models in which several
factors collectively determine the steady-state viral
burden in the asymptomatic phase.
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